The AGITG GAP Study: a Phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer

Andrew P. Barbour, Jaswinder S. Samra, Koroush S. Haghighi, Mark W. Donoghoe, Matthew Burge, Marion T. Harris, Yu Jo Chua, Jenna Mitchell, Nick O’Rourke, Howard Chan, Val J. Gebski, Sivakumar Gananadha, Daniel G. Croagh, James G. Kench, David Goldstein, Australasian Gastro-Intestinal Trials Group (AGITG) GAP investigators

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Background: While combination therapy with nab-paclitaxel/gemcitabine (nab-gem) is effective in pancreatic ductal adenocarcinoma (PDAC), its efficacy as perioperative chemotherapy is unknown. The primary objective of this multicenter, prospective, single-arm, phase II study was to determine whether neoadjuvant therapy with nab-gem was associated with higher complete resection rates (R0) in resectable PDAC, while the secondary objectives were to determine the utility of radiological assessment of response to preoperative chemotherapy and the safety and efficacy of nab-gem as perioperative therapy. Methods: Patients were recruited from eight Australian sites, and 42 patients with radiologically defined resectable PDAC and an Eastern Cooperative Oncology Group performance status of 0–2 were enrolled. Participants received two cycles of preoperative nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on days 1, 8, and 15 (28-day cycle) presurgery, and four cycles postoperatively. Early response to chemotherapy was measured with fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scans on day 15. Results: Preoperative nab-gem was completed by 93% of participants, but only 63% postoperatively. Thirty-six patients had surgery: 6 (17%) were unresectable, 15 (52%) had R0 (≥ 1 mm) resections, 14 (48%) had R1 (< 1 mm) resections, and 1 patient did not have PDAC. Median progression-free survival was 12.3 months and median overall survival (OS) was 23.5 months: R0 patients had an OS of 35 months versus 25.6 months for R1 patients after surgery. Seven patients had not progressed after 43 months. Conclusions: The GAP trial demonstrated that perioperative nab-gem was tolerable. Although the primary endpoint of an 85% R0 rate was not met, the R0 rate was similar to trials using a > 1 mm R0 resection definition, and survival rates were comparable with recent adjuvant studies.

Original languageEnglish
Pages (from-to)2506-2515
Number of pages10
JournalAnnals of Surgical Oncology
Issue number7
Early online date29 Jan 2020
Publication statusPublished - 1 Jul 2020


Dive into the research topics of 'The AGITG GAP Study: a Phase II study of perioperative gemcitabine and nab-paclitaxel for resectable pancreas cancer'. Together they form a unique fingerprint.

Cite this